A placebo-controlled trial of buspirone for the treatment of marijuana dependence.
The present study investigated the potential efficacy of buspirone for treating marijuana dependence. Participants received either buspirone (maximum 60mg/day) (n=23) or matching placebo (n=27) for 12 weeks, each in conjunction with motivational interviewing. In the modified intention-to-treat analysis, the percentage of negative UDS results in the buspirone-treatment group was 18 percentage points higher than the placebo-treatment group (95% CI: -2% to 37%, p=0.071). On self-report, participants receiving buspirone reported not using marijuana 45.2% of days and participants receiving placebo reported not using 51.4% of days (p=0.55). An analysis of participants that completed the 12-week trial showed a significant difference in the percentage negative UDS (95% CI: 7-63%, p=0.014) and a trend for participants randomized to the buspirone-treatment group who completed treatment to achieve the first negative UDS result sooner than those participants treated with placebo (p=0.054). Further study with buspirone in this population may be warranted; however, strategies to enhance study retention and improve outcome measurement should be considered in future trials.
McRae-Clark
Aimee L
AL
Department of Psychiatry, Medical University of South Carolina, 67 President Street, Charleston, SC 29425, USA. mcraeal@musc.edu
Carter
Rickey E
RE
Killeen
Therese K
TK
Carpenter
Matthew J
MJ
Wahlquist
Amy E
AE
Simpson
Stacey A
SA
Brady
Kathleen T
KT
D000328:Adult; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy / Q000209:etiology / Q000523:psychology; D002065:Buspirone / Q000009:adverse effects / Q000627:therapeutic use*; D002186:Cannabinoids / Q000652:urine; D002188:Cannabis / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D002189:Marijuana Abuse / Q000188:drug therapy* / Q000523:psychology / Q000652:urine; D009042:Motivation; D011569:Psychiatric Status Rating Scales; D018401:Sample Size; D013375:Substance Withdrawal Syndrome / Q000453:epidemiology / Q000523:psychology; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D014151:Anti-Anxiety Agents; D002186:Cannabinoids; D002065:Buspirone
Am J Addict. 2007 Sep-Oct;16(5):331-42
17882603
Naunyn Schmiedebergs Arch Pharmacol. 2000 Jan;361(1):19-24
10651142
Neurochem Res. 2005 Aug;30(8):1037-43
16258853
Drug Alcohol Depend. 1999 Apr 1;54(2):127-35
10217552
Am J Psychiatry. 2004 Nov;161(11):1967-77
15514394
Addict Behav. 1979;4(4):361-71
525504
Arch Gen Psychiatry. 2001 Aug;58(8):755-61
11483141
Addiction. 2001 Jul;96(7):1023-34
11440613
J Stud Alcohol Suppl. 1994 Dec;12:70-5
7723001
J Clin Pharmacol. 1994 Mar;34(3):222-4
8021329
Ther Drug Monit. 2005 Dec;27(6):799-810
16306858
Pharmacol Biochem Behav. 2003 Jul;75(4):777-87
12957219
Am J Addict. 2006 Sep-Oct;15(5):404
16966201
Psychopharmacologia. 1973 Oct 23;33(1):53-70
4358666
Curr Opin Psychiatry. 2006 May;19(3):233-8
16612207
Am J Addict. 2006 Jan-Feb;15(1):8-14
16449088
J Anal Toxicol. 1998 Oct;22(6):445-54
9788519
J Clin Psychopharmacol. 1990 Jun;10(3 Suppl):67S-76S
2198303
Addiction. 1999 Sep;94(9):1311-22
10615717
Biochem Pharmacol. 2001 Jun 1;61(11):1357-67
11331071
Exp Clin Psychopharmacol. 2000 Nov;8(4):483-92
11127420
Exp Clin Psychopharmacol. 2002 Feb;10(1):54-63
11866252
Br J Psychiatry Suppl. 1991 Sep;(12):45-51
1840763
Pharmacotherapy. 1997 May-Jun;17(3):497-510
9165553
J Consult Clin Psychol. 1993 Jun;61(3):455-61
8326047
Drug Alcohol Depend. 2004 Aug 16;75(2):123-34
15276217
JAMA. 1990 Nov 21;264(19):2511-8
2232018
J Clin Psychiatry. 2006 Feb;67(2):247-57
16566620
Psychopharmacology (Berl). 1982;76(3):245-50
6285406
Am J Addict. 2004 Jan-Feb;13(1):21-32
14766435
Clin Pharm. 1984 Nov-Dec;3(6):600-7
6150781
J Subst Abuse Treat. 2003 Jun;24(4):369-76
12867212
Arch Gen Psychiatry. 1994 Jul;51(7):568-76
8031230
Clin Pharmacol Ther. 1976 Mar;19(3):300-9
770048
Drug Alcohol Depend. 2008 Apr 1;94(1-3):254-7
18182254
Br J Med Psychol. 1959;32(1):50-5
13638508
Drug Metab Dispos. 1995 Aug;23(8):825-31
7493549
Int J Neuropsychopharmacol. 2006 Jun;9(3):277-86
15967059
Eur J Pharmacol. 1983 Mar 18;88(1):137-8
6133764
Eur J Pharmacol. 1974 Sep;28(1):172-7
4609777
Am J Drug Alcohol Abuse. 2002 Nov;28(4):643-52
12492261
Subst Use Misuse. 1997 Feb;32(3):249-64
9058474